Dextroamphetamine
- Generic Name
- Dextroamphetamine
- Brand Names
- Adderall, Dexedrine, Mydayis, Procentra, Xelstrym, Zenzedi
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N
- CAS Number
- 51-64-9
- Unique Ingredient Identifier
- TZ47U051FI
- Background
Dextroamphetamine is the dextrorotary enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.
- Indication
Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy
- Associated Therapies
- -
Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia
- First Posted Date
- 2015-02-13
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 58
- Registration Number
- NCT02363075
- Locations
- 🇫🇷
Groupe Hospitalier Pitie Salpetriere, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath